Abstract: A method of treating or preventing ectoparasite infestation in a plant or animal host is provided comprising applying an effective amount of at least one metalloprotease inhibitor and/or at least one metal chelating agent, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom.
Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
Type:
Application
Filed:
November 8, 2006
Publication date:
May 28, 2009
Applicant:
HELPERBY THERAPEUTICS LIMITED
Inventors:
Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart
Abstract: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Type:
Application
Filed:
October 18, 2006
Publication date:
May 21, 2009
Applicant:
MERCK & CO., INC.
Inventors:
Christopher J. Dinsmore, Ana Esther Gabarda Ortega, Jongwon Lim, Michelle R. Machacek, Alan B. Northrup, Jonathan R. Young
Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
Type:
Application
Filed:
November 17, 2006
Publication date:
May 21, 2009
Inventors:
Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
Abstract: The present invention is generally related to the modulation of cell growth or apoptosis. Compositions for modulating cell growth or apoptosis, methods of use thereof, and methods of identification thereof are described.
Abstract: The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.
Type:
Application
Filed:
May 15, 2006
Publication date:
April 16, 2009
Inventors:
Michel Belley, Jason Burch, John Colucci, Julie Farand, Mario Girard, Yongxin Han
Abstract: The present invention provides compounds of Formula (I) comprising: including salts, solvates, and physiologically functional derivatives thereof, pharmaceutical formulations containing them, processes for their preparation, and methods of treatment using them.
Type:
Application
Filed:
March 1, 2006
Publication date:
April 9, 2009
Inventors:
Kristjan Gudmundsson, John G. Catalano, Angilique Svolto
Abstract: The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: V. rigida (Esper, 1794) (order Verongida, family Aplysinidae) and S. aurea (Hyatt, 1875) (order Dictyoceratida, family Thorectidae), and a third S. cerebriformis (Duchassaing & Michelotti, 1864), is less common and separated based on subtle differences of morphology and coloration, from the other two species. Several compounds were isolated and were evaluated in established animal models predictive of neurological related drug function, namely, the rodent FST and the chick anxiety-depression model.
Type:
Application
Filed:
October 9, 2008
Publication date:
April 9, 2009
Inventors:
Mark T. Hamann, Anna J. Kochanowska, Abir El-Alfy, Rae R. Matsumoto, Angelo Boujos
Abstract: The present invention relates to novel fused bicyclicpyrrolidine pyridone compounds of the formula (I) wherein R, RP and n are as defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions and their use in treating addictive disorders such as the use of tobacco or other nicotine containing products and in the treatment of neurological and mental disorders related to a decrease in cholinergic function.
Type:
Application
Filed:
November 30, 2005
Publication date:
April 9, 2009
Inventors:
Brian T. O'Neill, Kristen J. Procko, Daniel Yohannes
Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
Abstract: The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.
Type:
Application
Filed:
November 7, 2008
Publication date:
March 12, 2009
Applicant:
Wyeth
Inventors:
Neelu Kaila, Silvano L. Debernardo, Kristin M. Janz, Raymond T. Camphausen, Patricia W. Bedard, Adrian Huang
Abstract: Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.
Type:
Application
Filed:
September 6, 2007
Publication date:
March 12, 2009
Inventors:
Paul Kiprono Chepkwony, Maria Medina, Mitchell Medina
Abstract: The subject invention provides useful and novel 5-HT3 antagonists. The subject invention also provides methods for synthesizing the compounds of invention. The invention also provides methods for the treatment of irritable bowel syndrome and other such conditions.
Type:
Grant
Filed:
October 20, 2006
Date of Patent:
March 10, 2009
Assignee:
ARYx Therapeutics, Inc.
Inventors:
Xiaoming Zhang, Jurg R. Pfister, Cyrus Becker, Pascal Druzgala
Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
Type:
Application
Filed:
February 2, 2007
Publication date:
March 5, 2009
Inventors:
Subharekha Raghavan, Darby Rye Schmidt, Steven L. Colletti, Abigail Lee Smenton
Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
Type:
Application
Filed:
April 10, 2006
Publication date:
March 5, 2009
Inventors:
Chixu Chen, Brian W. Eastman, Essa H. Hu
Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.
Type:
Application
Filed:
April 7, 2006
Publication date:
February 26, 2009
Inventors:
Jason E. Imbriglio, Steven L. Colletti, James R. Tata, Rui Liang, Subharekha Raghavan, Darby R. Schmidt, Abigail L. Smenton, Sook Yee Chan
Abstract: The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase inhibitor and a hormone targeted drug to an individual with cancer. In specific embodiments, the histone deacetylase inhibitor and the hormone targeted drug act synergistically to treat the cancer, including by overcoming resistance to a cancer therapy.
Type:
Application
Filed:
June 6, 2008
Publication date:
February 19, 2009
Inventors:
Angela Brodie, Vincent Njar, Gauri Sabnis, Lalji Gediya
Abstract: The present disclosure relates to pyridoindolone derivatives of general formula (I): in which R1 to R5 are as defined in the specification, to processes for preparing said derivatives, and to methods of use thereof.
Type:
Application
Filed:
October 16, 2008
Publication date:
February 12, 2009
Applicant:
SANOFI-AVENTIS
Inventors:
Bernard BOURRIE, Pierre CASELLAS, Jean-Marie DEROCQ, Samir JEGHAM, Yvette MUNEAUX
Abstract: The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.
Type:
Application
Filed:
June 30, 2006
Publication date:
February 12, 2009
Applicant:
Pierre Fabre Medicament
Inventors:
Hugues Bienayme, Antoine Dumoulin, Serge Grisoni, Bachir Kaloun El, Stephane Poigny, Remi Rabot, Rachid Rahali, Eric Tam, Pascaline Klein, Karim Bedjeguelal, Houcine Rahali
Abstract: The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.
Type:
Application
Filed:
August 1, 2008
Publication date:
February 12, 2009
Applicant:
SANOFI-AVENTIS
Inventors:
Laurent DUBOIS, Yannick EVANNO, Luc EVEN, Catherine GILLE, Andre MALANDA, David MACHNIK, Nathalie RAKOTOARISOA
Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. A1 and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl, Q is N, +NR, or CR4. The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.
Type:
Application
Filed:
May 25, 2007
Publication date:
January 29, 2009
Inventors:
James M. Chen, Xiaowu Chen, Maria Fardis, Haolun Jin, Choung U. Kim, Laura N. Schacherer
Abstract: The compounds of formula I in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.
Type:
Application
Filed:
September 23, 2008
Publication date:
January 29, 2009
Applicant:
Altana Pharma AG
Inventors:
Dieter Flockerzi, Rolf-Peter Hummel, Felix Reutter
Abstract: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
Abstract: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
Type:
Application
Filed:
August 27, 2004
Publication date:
January 15, 2009
Inventors:
Kyle J. Lindstrom, Hugues M.H. Martin, Bryon A. Merrill, Michael J. Rice, Joshua R. Wurst, Chad A. Haraldson, Tushar A. Kshirsagar, Philip D. Heppner, Shri Niwas, George W. Griesgraber, Matthew R. Radmer
Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Type:
Application
Filed:
July 9, 2007
Publication date:
January 8, 2009
Inventors:
Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.
Abstract: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
Type:
Application
Filed:
June 25, 2008
Publication date:
January 8, 2009
Inventors:
Alexander Graham Dossetter, Nicola Murdoch Heron
Abstract: Nucleotide-competing reverse transcriptase inhibitors (NcRTI) bind to the active site of HIV reverse transcriptase (RT) in competition with the next incoming nucleotide. To further investigate the impact of RT inhibitor resistance mutations on the activity of NcRTIs, the susceptibility of >6000 recent clinical isolates for a prototype compound, NcRTI-1, was determined. Over 80% of the profiled clinical isolates remained susceptible for NcRTI-1 (FC<4). No cross-resistance was observed between NcRTI-1 and currently used RT inhibitors, apart from limited cross-resistance with 3TC/FTC. Analysis of the genotype of >1700 of these viruses showed that the combination of active site mutations M184V+Y115F correlated most with resistance to NcRTI-1 (FC=75). Analysis also indicated that the K65R mutation is associated with hypersusceptibility to NcRTI-1 and that it reverses the reduced susceptibility caused by M184V. These findings were confirmed in SDM strains.
Type:
Application
Filed:
February 5, 2007
Publication date:
January 8, 2009
Inventors:
Dirk Edward Desire Jochmans, Piet Tom Bert Paul Wigerinck
Abstract: The compounds of formula I in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.
Type:
Grant
Filed:
August 29, 2003
Date of Patent:
December 30, 2008
Assignee:
Nycomed GmbH
Inventors:
Dieter Flockerzi, Rolf-Peter Hummel, Felix Reutter
Abstract: Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.
Type:
Application
Filed:
August 18, 2008
Publication date:
December 25, 2008
Applicant:
AMR TECHNOLOGY, INC.
Inventors:
James P. Beck, Anthony D. Pechulis, Arthur E. Harms
Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.
Type:
Application
Filed:
June 18, 2008
Publication date:
December 25, 2008
Applicant:
ASTRAZENECA AB
Inventors:
Hui-Fang Chang, Marc Chapdelaine, Bruce Thomas Dembofsky, Keith John Herzog, Carey Horchler, Richard Jon Schmiesing
Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
Type:
Application
Filed:
July 18, 2008
Publication date:
December 18, 2008
Inventors:
Michael G. Kelly, Satyanarayana Janagani, Ravindra B. Upasani
Abstract: The invention relates to the use of compounds of the general formula (I) wherein R, R?=H, C1-5-hydrocarbon radical, —O—C1-5-oxyhydrocarbon radical and are identical or different, R1, R2, R3=H, C1-5-hydrocarbon radical and are identical or different, X, Y=—O—; —O—C(O)—; —(O)C—O— and are identical or different, A=A?=—O—C(O)—O—; A?=R4—CH2C(CH2—)3, A?=—C(H)-isopropyl, R4=R4?=—CH3; R4?=—[CH2—CH(R1)]e—(Y)d—(CH2)c-Ph(R)a, a, b=1 to 5 and are identical or different, c, k=0 to 5 and are identical or different, d, h=0 or 1 and are identical or different, e, g=0 or 1 and are identical or different, f=0 or 1, m=1 to 3, n=0 or 1, as solubilizing agents/solvents for dissolving organic UV filters.
Type:
Grant
Filed:
April 14, 2005
Date of Patent:
December 16, 2008
Assignee:
Goldschmidt GmbH
Inventors:
Christoph Schunicht, Burghard Gruning, Pawel Grzebyk, Klaus Jenni
Abstract: The present invention relates to Benzo[c][2,7]naphthyridine Derivatives, compositions comprising an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for modulating PDK-1 activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c][2,7]naphthyridine Derivative.
Type:
Application
Filed:
March 4, 2008
Publication date:
November 27, 2008
Applicant:
WYETH
Inventors:
Allan WISSNER, Middleton Brawner FLOYD, JR., Russell DUSHIN, Heidi L. FRASER, Yongbo HU, Andreas MADERNA, Thomas NITTOLI, Yanong Daniel WANG
Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.
Type:
Application
Filed:
March 13, 2008
Publication date:
November 27, 2008
Applicant:
Biovitrum AB (publ.)
Inventors:
Johan Angbrant, Peter Brandt, Rune Ringom, Bengt Lindqvist
Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract: The present invention relates to new tetrahydro-?-carbolin-sulfonamide derivatives of general formula (I), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding physiologically acceptable salts or corresponding solvates. These compounds are suitable as pharmacologically active agents in a medicament for the prophylaxis and/or treatment of disorders or diseases related to 5-HT6 receptors. The invention also relates to two different methods for obtaining the mentioned compounds and to pharmaceutical compositions containing them.
Type:
Application
Filed:
July 26, 2006
Publication date:
November 13, 2008
Applicant:
LABORATORIES DEL DR. ESTEVE, S.A.
Inventors:
Jose Luis Diaz-Fernandez, Ramon Merce-Vidal, Joerg Holenz
Abstract: Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*109/L or a decrease in median absolute neutrophil count by about 1.42*109/L.
Abstract: The invention encompasses a series of tetrahydrocarboline compounds of Formula I which inhibit HIV entry by attaching to the exterior viral envelop protein gp120 and interrupting the viral entry process, possibly by interfering with the cellular receptor CD4. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Type:
Grant
Filed:
May 20, 2005
Date of Patent:
November 11, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Edward H. Ruediger, Daniel H. Deon, John F. Kadow
Abstract: This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment of alleviation of diseases or disorders associated with, or mediated by a drop in extra cellular pH.
Abstract: This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
Abstract: The disclosure relates to compounds of formula (I): wherein R1, R2, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and therapeutic use thereof.
Type:
Application
Filed:
April 9, 2008
Publication date:
October 23, 2008
Applicant:
SANOFI-AVENTIS
Inventors:
Yvette MUNEAUX, Samir JEGHAM, Bernard BOURRIE, Pierre CASELLAS, Paola CIAPETTI, Jean-Marie DEROCQ, Camille-Georges WERMUTH
Abstract: The present invention represents novel optical isomers produced according the invention that are optic antipodes to each other having individual biological activity which can be used as active ingredients in pharmaceutical compositions with nootropic and sedative activity for treatment of different individual conditions of patients.
Type:
Application
Filed:
September 12, 2005
Publication date:
October 23, 2008
Inventors:
Ramiz Medzhidovich Salimov, Georgy Ivanovich Kovalev, Maria Nikolaevna Preobrazhenskaya, Sergey Nikolaevich Lavrenov, Sergey Alexandrovich Lakatosh
Abstract: The invention relates to novel heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a method for preparing these compounds, and to their use as medicaments, in particular as antibacterials and ?-lactamase inhibitors.
Type:
Grant
Filed:
December 4, 2003
Date of Patent:
October 21, 2008
Assignee:
Novexel
Inventors:
Maxime Lampilas, Branislav Musicki, Michel Klich, David Alan Rowlands
Abstract: The invention provides methods and compositions for treating hyperlipidemia and disorders associated with hyperlipidemia in a mammal. Compositions useful in the practice of the invention include a microsomal triglyceride transport protein inhibitor (“MTPI”) and at least two other cholesterol lowering drugs selected from the group consisting of a cholesterol absorption inhibitor (“CAI”), a HMG-CoA reductase inhibitor, a bile acid sequestrant, a fibric acid derivative, niacin, and squalene synthetase inhibitor.
Abstract: This invention relates to compositions including a compound of Formula I wherein R is selected from a C1-C6 alkyl, unsubstituted phenyl or phenyl substituted by one or more halo, C1-C6 alkyl or C1-C6 alkoxy, combinations of a compound of formula I with other chemotherapeutic agents, and the use of the compositions or combinations for the treatment of cellular proliferative disorders.
Type:
Application
Filed:
April 4, 2008
Publication date:
October 9, 2008
Applicant:
Auckland Uniservices Limited
Inventors:
Bruce Charles Baguley, Elaine Shirley Marshall, Catherine Jean Drummond